Can a patient currently taking paroxetine (Paxil) 10 mg be started on atomoxetine (Strattera) 20 mg daily?

Can Strattera 20mg be Started in a Patient on Paxil 10mg?

Yes, atomoxetine (Strattera) 20 mg daily can be started in a patient taking paroxetine (Paxil) 10 mg, but the atomoxetine dose must be reduced and titrated more cautiously due to a major pharmacokinetic drug interaction that will increase atomoxetine exposure approximately 6-fold.

Critical Drug Interaction

Paroxetine is a potent CYP2D6 inhibitor that dramatically alters atomoxetine metabolism, converting extensive metabolizers into functional poor metabolizers. 1

Magnitude of the Interaction

• Paroxetine increases atomoxetine AUC by approximately 6.5-fold and Cmax by 3.5-fold 1
• This interaction results in atomoxetine plasma concentrations similar to those seen in genetic CYP2D6 poor metabolizers 1
• The half-life of atomoxetine increases approximately 2.5-fold when combined with paroxetine 1
• Even at lower paroxetine doses (20 mg), atomoxetine exposure increases 5.8-fold 2

Metabolic Pathway Changes

When paroxetine is co-administered with atomoxetine: 3, 1

• Formation of the primary metabolite 4-hydroxyatomoxetine is markedly reduced
• N-desmethylatomoxetine concentrations increase as metabolism shifts to this minor pathway
• The genotype-dependent differences in atomoxetine pharmacokinetics are eliminated—all patients behave like poor metabolizers 3

Dosing Recommendations for This Combination

The starting dose of atomoxetine should be reduced when used with paroxetine, and titration must proceed more slowly than usual.

Practical Dosing Strategy

• Start atomoxetine at 20 mg daily (the dose you proposed is acceptable as a starting point) 4
• Monitor closely for adverse effects during the first 24-48 hours and throughout dose adjustments 5
• Titrate more slowly than standard protocols—wait at least 2-3 weeks between dose increases rather than the typical 1 week 4
• Target a lower maximum dose than would be used without the interaction
• Expect therapeutic effects at lower atomoxetine doses than usual due to the 6-fold increase in exposure 2, 1

Monitoring Requirements

Close monitoring is essential for: 6, 4

• Cardiovascular parameters: Heart rate and blood pressure (atomoxetine can increase both by 1-4 mmHg and 1-2 bpm, though this may be more pronounced with elevated drug levels) 6
• Gastrointestinal symptoms: Nausea, vomiting, abdominal pain (especially common with rapid atomoxetine dose escalation) 6
• CNS effects: Somnolence, dizziness, irritability 6
• Appetite and weight: Decreased appetite is common with atomoxetine 6
• Suicidal ideation: FDA black box warning applies to atomoxetine, particularly important during dose initiation and changes 6, 7

Safety Considerations

Cardiovascular Assessment

Before initiating atomoxetine, obtain: 6

• Personal history of cardiac symptoms
• Family history of sudden death, cardiovascular disease, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, or long QT syndrome
• Consider ECG if any risk factors are present 6

Common Pitfalls to Avoid

• Do not use standard atomoxetine titration schedules—the 6-fold increase in exposure means standard doses will result in poor metabolizer-level concentrations 1
• Do not assume lack of response means inadequate dosing—the patient is already receiving much higher effective exposure than the nominal dose suggests 2
• Do not abruptly discontinue paroxetine if the patient is stable on both medications, as this will cause a sudden 6-fold drop in atomoxetine levels 8

Alternative Consideration

If this combination proves difficult to manage due to adverse effects, consider: 9

• Using atomoxetine alone (discontinue paroxetine with appropriate taper) 8
• Selecting a different antidepressant with minimal CYP2D6 inhibition if the patient requires both medications 8

Clinical Context

Atomoxetine is FDA-approved for ADHD treatment and has demonstrated efficacy in both children and adults. 6, 7 While stimulants remain first-line for ADHD, atomoxetine is particularly useful for patients with: 7, 9

• Comorbid anxiety disorders (common with depression/paroxetine use)
• Substance abuse risk or history
• Preference to avoid controlled substances
• Inadequate response or intolerance to stimulants

The combination of paroxetine and atomoxetine is pharmacologically feasible and has been studied in controlled settings, but requires dose adjustment and enhanced monitoring. 3, 2, 1